The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase

The receptor tyrosine kinase family consisting of Tyro3, Axl, and Mer (TAM) is one of the most recently identified receptor tyrosine kinase families. TAM receptors are up-regulated postnatally and maintained at high levels in adults. They all play an important role in immunity, but Axl has also been implicated in cancer and therefore is a target in the discovery and development of novel therapeutics. However, of the three members of the TAM family, the Axl kinase domain is the only one that has so far eluded structure determination. To this end, using differential scanning fluorimetry and hydrogen-deuterium exchange mass spectrometry, we show here that a lower stability and greater dynamic nature of the Axl kinase domain may account for its poor crystallizability. We present the first structural characterization of the Axl kinase domain in complex with a small-molecule macrocyclic inhibitor. The Axl crystal structure revealed two distinct conformational states of the enzyme, providing a first glimpse of what an active TAM receptor kinase may look like and suggesting a potential role for the juxtamembrane region in enzyme activity. We noted that the ATP/inhibitor-binding sites of the TAM members closely resemble each other, posing a challenge for the design of a selective inhibitor. We propose that the differences in the conformational dynamics among the TAM family members could potentially be exploited to achieve inhibitor selectivity for targeted receptors.

[1]  M. Prados,et al.  Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas , 2016, Oncotarget.

[2]  Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase , 2016, Cell Communication and Signaling.

[3]  Zheng-chao Tu,et al.  4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors. , 2016, Journal of medicinal chemistry.

[4]  G. Getz,et al.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.

[5]  Valentina Abet,et al.  State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist. , 2015, European journal of medicinal chemistry.

[6]  K. Davies,et al.  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.

[7]  B. Halmos,et al.  AXL kinase as a novel target for cancer therapy , 2014, Oncotarget.

[8]  I. Lax,et al.  Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities , 2014, eLife.

[9]  G. Chevé,et al.  Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors , 2014, Molecular Cancer Therapeutics.

[10]  Wei Liu,et al.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.

[11]  Jae Cheol Lee,et al.  MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. , 2014, Cancer research.

[12]  G. Lemke Biology of the TAM receptors. , 2013, Cold Spring Harbor perspectives in biology.

[13]  C. Sheridan First Axl inhibitor enters clinical trials , 2013, Nature Biotechnology.

[14]  D. Cyranoski iPS cells in humans , 2013, Nature Biotechnology.

[15]  Wei Lu,et al.  Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met. , 2013, Journal of medicinal chemistry.

[16]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[17]  S. Frye,et al.  Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. , 2012, ACS medicinal chemistry letters.

[18]  N. Powell,et al.  Novel and selective spiroindoline-based inhibitors of Sky kinase. , 2012, Bioorganic & medicinal chemistry letters.

[19]  Anupam Verma,et al.  Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. , 2011, ACS medicinal chemistry letters.

[20]  D. Bearss,et al.  Targeting Axl and Mer Kinases in Cancer , 2011, Molecular Cancer Therapeutics.

[21]  T. Rosenberg,et al.  A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases , 2011, Molecular vision.

[22]  P. Darke,et al.  Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met , 2011, The Journal of Biological Chemistry.

[23]  S. Steinbacher,et al.  The crystal structure of a constitutively active mutant RON kinase suggests an intramolecular autophosphorylation hypothesis. , 2010, Biochemistry.

[24]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[25]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[26]  Pao-Chun Lin,et al.  Cytoplasmic ACK1 Interaction with Multiple Receptor Tyrosine Kinases Is Mediated by Grb2 , 2009, The Journal of Biological Chemistry.

[27]  Joel Greshock,et al.  Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. , 2009, Cancer research.

[28]  A. Pozzi,et al.  The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.

[29]  John Kuriyan,et al.  Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.

[30]  J. Christensen,et al.  Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. , 2009, Biochemistry.

[31]  G. Feldmann,et al.  The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target , 2009, Cancer biology & therapy.

[32]  Xudong Huang,et al.  Structural insights into the inhibited states of the Mer receptor tyrosine kinase , 2009, Journal of structural biology.

[33]  Ming-Tseh Lin,et al.  Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. , 2008, Cancer letters.

[34]  G. Lemke,et al.  Immunobiology of the TAM receptors , 2008, Nature Reviews Immunology.

[35]  A. Ullrich,et al.  Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[36]  H. Earp,et al.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.

[37]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[38]  H. Garewal,et al.  A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors , 2007, Oncogene.

[39]  T. Pawson,et al.  A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases , 2006, The EMBO journal.

[40]  Qingxian Lu,et al.  TAM receptor function in the retinal pigment epithelium , 2006, Molecular and Cellular Neuroscience.

[41]  R. Birge,et al.  Phosphatidylserine recognition by phagocytes: a view to a kill. , 2006, Trends in cell biology.

[42]  R. Timpl,et al.  Structural basis for Gas6–Axl signalling , 2006, The EMBO journal.

[43]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[44]  Stevan R. Hubbard,et al.  Juxtamembrane autoinhibition in receptor tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[45]  D. Murphy Determination of accurate KI values for tight-binding enzyme inhibitors: an in silico study of experimental error and assay design. , 2004, Analytical biochemistry.

[46]  B. Dahlbäck,et al.  Ligand Recognition and Homophilic Interactions in Tyro3 , 2004, Journal of Biological Chemistry.

[47]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[48]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[49]  Qingxian Lu,et al.  Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family , 2001, Science.

[50]  R. Scott,et al.  Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.

[51]  S. Jacobson,et al.  Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa , 2000, Nature Genetics.

[52]  S. Goff,et al.  Tyro-3 family receptors are essential regulators of mammalian spermatogenesis , 1999, Nature.

[53]  A. Ullrich,et al.  Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site , 1997, Oncogene.

[54]  H. Hanafusa,et al.  Identification of the Product of Growth Arrest-specific Gene 6 as a Common Ligand for Axl, Sky, and Mer Receptor Tyrosine Kinases* , 1996, The Journal of Biological Chemistry.

[55]  H. Kung,et al.  Identification of the Major Autophosphorylation Sites of Nyk/Mer, an NCAM-related Receptor Tyrosine Kinase* , 1996, The Journal of Biological Chemistry.

[56]  Pamela F. Jones,et al.  The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases , 1995, Cell.

[57]  H. Yamane,et al.  Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6 , 1995, Nature.

[58]  J F Morrison,et al.  Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.